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Have you ever wondered why some inflammatory diseases resolve while others 
persist? For example acute gout is a self-limiting disease whereas rheumatoid arthritis 
persists. A frozen shoulder (adhesive capsulitis) nearly always “gets better” while 
osteoarthritis does not.  Furthermore a common feature of many rheumatic diseases, and 
one that clinical rheumatologists rely on to help them make a diagnosis, is that most forms 
of arthritis have a predilection for particular joints, and even tendons rather than the joint 
itself. For example osteoarthritis and psoriatic arthritis often involve the distal 
interphalangeal joints, whereas rheumatoid arthritis is more often symmetrical and more 
commonly affects the MCP joints. In contrast ankylosing spondylitis mainly targets spinal 
ligaments and enthesial tissue. The cellular and molecular basis for disease persistence and 
tissue tropism has until now remained enigmatic but recent findings suggest that tissue 
resident stromal cells such as fibroblasts provide an unexpected answer to these questions. 
(1) 
Fibroblasts are mesenchymal cells that provide the cellular infrastructure for organs, 
as well as lining mesodermal membranes such as the synovial membrane. They are mostly 
involved in the deposition and resorption of the extracellular matrix (ECM) and help 
maintain tissue homeostasis. Fibrotic diseases such as systemic sclerosis have typically been 
thought to be driven by pathogenic fibroblasts. However, fibroblasts are far more than just 
structural cells involved in pathology (2). They are sensitive to environmental changes and 
both produce and respond to a range of cytokines and chemokines. They respond in a very 
specific manner to different stimuli and actively influence not only the composition of the 
ECM but also the degree of inflammation within and destruction of barrier membranes such 
as the synovium (2)  
Under inflammatory conditions, fibroblasts act as organ-specific, innate immune 
system sentinel cells where they are involved in the switch from acute resolving to chronic 
persisting inflammation (3). For example, fibroblast-like synoviocytes (FLS) play a critical role 
in the pathogenesis of RA and possess a characteristic, invasive, and activated phenotype 
(4). In addition to contributing to the recruitment and emigration of inflammatory cells to 
and out of the joint, they modulate the survival and behaviour of infiltrating leucocytes. It is 
now clear that fibroblasts can exist in discrete subsets, some of which are pro-inflammatory 
while others, more functionally similar to mesenchymal stromal cells (MSC), are anti-
inflammatory and regulate tissue homeostasis and organ repair (5). More importantly, FLS 
are crucial components in the hyperplastic lining layer and in cartilage destruction. New data 
raise the possibility of epigenetically programmed aggressive cells “spreading” arthritis from 
inflamed to uninflamed joints in the early stages of arthritis, but at the same time offering 
the possibility of specifically targeting stromal subpopulations of choice. (6).  
Work over the last decade has demonstrated that fibroblasts modify the quality, 
quantity and duration of leucocyte accumulation within tissues. They also contribute to the 
resolution of inflammation by normalizing chemokine gradients, thereby allowing infiltrating 
leukocytes to leave the tissue through the draining lymphatics. We have proposed that 
inflammation is contextual and since fibroblasts help define tissue topography we have 
suggested that fibroblasts represent an attractive, site specific, therapeutic target (7).  
The introduction of biologic treatments that deplete leucocytes and their secreted 
products has led to a step-change in the management of IMIDs. However these therapies do 
not reverse tissue damage and do not result in a cure. A significant proportion of patients 
continue to have stubbornly resistant disease. Moreover many patients, in whom clinical 
remission has been achieved, subsequently relapse once treatment is withdrawn, suggesting 
that additional therapeutic targets, such as fibroblasts that are responsible for complete 
resolution of inflammation, remain to be discovered. 
Inflammation results from the complex interaction between haematopoietic and 
stromal cells. Yet almost all current therapies target haematopoietic cells and ignore stromal 
cells, such as fibroblasts. Therefore an understanding of the origins and functional 
consequences of “pathogenic fibroblasts” as opposed to their physiological counterparts 
provides the scientific basis for new therapies based on reversing the persistence of disease.  
For example fibroblasts express Toll-like Receptors and other pattern recognition receptors. 
In RA they express a specific pattern of coding and non-coding (small and long) RNA that 
distinguishes them from non-RA synovial fibroblasts and are endogenously activated due to 
epigenetic imprinting for tissue destructive pathways (8). Like an anti-cancer tissue 
response, it is tempting to propose that inflammation creates an anti-tissue response that 
spreads from the original site to distant predisposed sites where they are particularly 
susceptible to immune attack. Strikingly, fibroblasts maintain their diversity, topographic 
differentiation and positional memory in culture. Emerging data have shown site, stage and 
disease specific differences in the coding and noncoding fibroblast transcriptome. (9).   
Despite their biological importance, remarkably little is known about how fibroblast 
numbers and subsets change during inflammation.  Difficulties in accessing patients with 
very early disease, sampling the tissue involved and the lack of good fibroblast markers have 
all proved obstacles to such work (1). However, stromal cells such as fibroblasts are a 
functionally heterogeneous group of cells with some displaying pro-inflammatory and 
destructive properties, whereas others are immune-regulatory and help facilitate tissue 
repair. This has led to a therapeutic dilemma. Which cells should be targeted or replaced 
and which should be retained? A clear understanding of the biology and significance of 
fibroblast heterogeneity is therefore essential to provide a coherent rationale for their use in 
the future treatment of IMIDs. In the meantime fibroblasts biology rather like Cinderella 
haves joined leucocytes and their cell products at the “Rheumatology ball”.   
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